Market Assessment of a novel magnetic resonance imaging platform for long-term In-vivo cell tracking

用于长期体内细胞追踪的新型磁共振成像平台的市场评估

• 批准号: 561439-2021
• 负责人: Cheng, HaiLing
• 金额: $ 1.09万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=724158
• 关键词: Market; Assessment; novel; magnetic; resonance

This proposal seeks to fund a market assessment of a novel magnetic resonance imaging (MRI) platform for sensitive and long-term tracking of therapeutic cells deep in the body. Therapeutic cells, such as stem cells, are used to repair damaged tissue and grow new ones. Currently, stem cells are used to treat patients with leukemia or other blood disorders. Many other tissue targets are under intense development worldwide but have not advanced into the clinic, including stem cell therapy to treat the brain and nervous system, heart, liver, kidneys, and skeletal muscle. While each organ has its own set of specific challenges and some are decades away from benefiting patients, a common hurdle is the current gap in our ability to monitor cells in the body. In preclinical animal studies, it is extremely difficult to optimize the ingredients for successful therapy without a way to look deep into the body and see if transplanted cells stay, grow, and contribute to new function. Eventually, in human stem cell transplant patients, it would be extremely valuable if we had a way to monitor the progress and success of therapy.The Cheng Lab has discovered a new mechanism for creating bright signal from cells, even human stem cells. This platform is based on MRI and offers the unique combination of high-sensitivity, long-term cell tracking, deep-tissue imaging, and non-invasiveness. Existing cell tracking technologies offer either high sensitivity or long-term tracking, not both, and may involve ionizing radiation. Briefly, our technology turns on the bright signal from stem cells at any time post-transplantation. Signal is generated only in cells that remain alive. In this way, one can determine and localize cell survival and their integration in new tissue. The group has filed a provisional patent and is working towards a PCT patent. The market assessment is the first step towards securing additional I2I funding that will be key in developing this cell tracking MRI platform into a research tool for a vast expanse of preclinical research.

该提案旨在资助一种新型磁共振成像（MRI）平台的市场评估，用于敏感和长期跟踪身体深处的治疗细胞。治疗性细胞，如干细胞，用于修复受损组织和生长新组织。目前，干细胞用于治疗白血病或其他血液疾病患者。许多其他组织靶点在全世界范围内都在加紧开发，但尚未进入临床，包括治疗大脑和神经系统、心脏、肝脏、肾脏和骨骼肌的干细胞疗法。虽然每个器官都有自己的一系列具体挑战，有些器官还需要几十年才能使患者受益，但一个共同的障碍是我们目前在监测体内细胞方面的能力存在差距。在临床前动物研究中，如果没有办法深入观察身体，看看移植的细胞是否停留，生长并有助于新的功能，那么很难优化成功治疗的成分。最终，在人类干细胞移植患者中，如果我们有一种方法来监测治疗的进展和成功，那将是非常有价值的。Cheng实验室发现了一种新的机制，可以从细胞，甚至是人类干细胞中产生明亮的信号。该平台基于MRI，提供了高灵敏度、长期细胞跟踪、深层组织成像和非侵入性的独特组合。现有的细胞跟踪技术要么提供高灵敏度，要么提供长期跟踪，而不是两者兼而有之，并且可能涉及电离辐射。简而言之，我们的技术在移植后的任何时候都能打开干细胞发出的明亮信号。信号只在存活的细胞中产生。通过这种方式，可以确定和定位细胞存活及其在新组织中的整合。该集团已提交了临时专利，并正在努力争取PCT专利。市场评估是获得额外I2I资金的第一步，这将是将该细胞跟踪MRI平台开发为广泛临床前研究的研究工具的关键。